Prognoza
Średnia cena docelowa analityków wynosi 4,56 € (+178,05%). Mediana wynosi 4,56 € (+178,05%).
| Kupuj |
4 |
| Trzymaj |
0 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
Eledon applies to FDA for Tegoprubart indication in islet cell transplantation
Eledon has filed an investigational new drug (IND) application with the FDA for a registration‑enabling study of the anti‑CD40L antibody Tegoprubart for immunosuppression in islet cell transplants for type 1 diabetes. The study would be Eledon’s first company‑sponsored trial in this area; investigator‑initiated studies are already underway at UChicago, Duke and MGH, and compassionate‑use treatments are also being provided. Earlier results in 12 treated patients showed insulin independence, HbA1c <7.0% and stable graft function for up to 22 months; Eledon also plans to start the global phase‑3 LEGACY study in kidney transplantation in Q4 2026 with about 600 patients. » Więcej na de.investing.com
Eledon Pharmaceuticals presents phase‑2 results and plans phase‑3 alignment with FDA
At the Leerink conference, Eledon Pharmaceuticals presented data on tegoprubart in kidney transplants, showing non‑inferiority to tacrolimus and a better safety profile, but no statistically significant superiority in kidney function. The company plans to finalize the phase‑3 study design with the FDA by year‑end and aims to start the trial within the year. Eledon received orphan‑drug designation for liver transplantation, is planning a liver‑related investigator‑sponsored trial (IST), and is evaluating expansion and strategic partnerships in islet‑cell transplantation. Cash on hand exceeds $130 million, providing a runway into the second quarter of next year. » Więcej na de.investing.com
Eledon Pharmaceuticals plans phase‑3 for Tegoprubart despite missed endpoints
At the Guggenheim Summit Eledon Pharmaceuticals said Tegoprubart showed significant safety advantages in kidney transplant studies, but the phase‑2 BESTOW trial missed its primary endpoint for renal function. The company plans to start a registrational phase‑3 trial with a composite endpoint by the end of 2026 and intends to place greater emphasis on patient‑reported outcomes. Positive early results in islet‑cell transplantation are to be advanced into a sponsored study in 2026, with an IND filing planned by year‑end. Eledon has funding into the second quarter of 2027 and is also pursuing global collaborations in xenotransplantation. » Więcej na de.investing.com
Eledon: 24-month data on tegoprubart show improved kidney function and no rejections
Eledon presented 24-month follow-up data from eight patients in the phase‑1b study of tegoprubart in kidney transplantation. Mean eGFR increased from 67.0 ml/min/1.73 m² at 12 months to 74.2 ml/min/1.73 m² at 24 months; there were no biopsy‑confirmed acute rejection episodes, graft losses, deaths, new-onset diabetes, or donor-specific antibodies reported. Tegoprubart is an anti‑CD40L antibody being investigated as a non‑lymphocyte‑depleting immunomodulatory therapy. Financials show a solid balance sheet with a high current ratio and more cash than debt, providing runway for the clinical programs. » Więcej na de.investing.com
Eledon Pharmaceuticals stock rises after positive Tegoprubart data on islet cell transplantation
Eledon Pharmaceuticals’ stock climbed about 3.3% in after-hours trading following preliminary study results for Tegoprubart in type 1 diabetes. In the ongoing University of Chicago Medicine trial, all six initial patients achieved insulin independence after one or two islet cell transplants, some for more than a year, accompanied by low HbA1c levels. Tegoprubart was well tolerated with no serious infections, thromboembolic events, rejection, or signs of kidney or neurological toxicity. The study has been expanded to 12 participants and is funded by Breakthrough T1D, which also plans to support a second study in patients with chronic kidney disease. » Więcej na de.investing.com
Dane finansowe
W ostatnim kwartale Eledon Pharmaceuticals osiągnęła przychody w wysokości 0 € i zysk netto w wysokości -3,47 mln €
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | 0 | - |
| Zysk netto | -3,47 mln | 76,66% |
| EBITDA | -3,47 mln | 76,66% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 146,25 mln € |
Liczba akcji | 84,46 mln |
Maksimum/minimum z 52 tygodni | 4,09 € - 1,23 € |
| Dywidendy | Nie |
Beta | 0,85 |
C/Z (PE Ratio) | -2,41 |
PEG (PEG Ratio) | 0,17 |
C/WK (PB Ratio) | 3,12 |
C/S (PS Ratio) | 0,00 |
Profil spółki
Eledon Pharmaceuticals, Inc., firma biofarmaceutyczna na etapie badań klinicznych, koncentruje się na opracowywaniu leków dla pacjentów cierpiących na choroby autoimmunologiczne i stwardnienie zanikowe boczne (ALS) oraz wymagających przeszczepu narządu lub przeszczepu komórkowego. Jej wiodącym kandydatem na lek jest AT-1501, humanizowane przeciwciało monoklonalne skierowane przeciw ligandowi CD40, czyli cząsteczce ekspresjonowanej na powierzchni limfocytów T układu odpornościowego człowieka. Lek znajduje się w badaniach klinicznych fazy 2a w leczeniu ALS oraz w badaniach klinicznych fazy 2 w przeszczepie wysp trzustkowych w leczeniu cukrzycy typu 1. Firma była wcześniej znana jako Novus Therapeutics, Inc. i zmieniła nazwę na Eledon Pharmaceuticals, Inc. w styczniu 2021 roku. Siedziba Eledon Pharmaceuticals, Inc. znajduje się w Irvine w Kalifornii.
| Nazwa | Eledon Pharmaceuticals |
| CEO | David-Alexandre C. Gros |
| Siedziba | Irvine,
ca Stany Zjednoczone |
| Strona internetowa | |
| Sektor | Materiały podstawowe |
| Branża | Chemikalia |
| Debiut giełdowy | 17.09.2014 |
| Pracownicy | 33 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | ELDN |
Frankfurt | 2TK.F |
München | 2TK.MU |
Düsseldorf | 2TK.DU |